Market Cap : 125.12 B | Enterprise Value : 138.67 B | PE Ratio : 25.25 | PB Ratio : 2.38 |
---|
NYSE:MDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2022-08-11), Medtronic's Intrinsic Value: Projected FCF is $68.66. The stock price of Medtronic is $94.17. Therefore, Medtronic's Price-to-Intrinsic-Value-Projected-FCF of today is 1.4.
The historical rank and industry rank for Medtronic's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Medtronic was 6.91. The lowest was 0.78. And the median was 1.89.
The historical data trend for Medtronic's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medtronic's Intrinsic Value: Projected FCF, along with its competitors' market caps and Intrinsic Value: Projected FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Intrinsic Value: Projected FCF distribution charts can be found below:
* The bar in red indicates where Medtronic's Intrinsic Value: Projected FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Medtronic's Free Cash Flow(6 year avg) = $5,275.52.
Medtronic's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Apr22) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | 5275.52 | + | 52551 | * | 0.8) | / | 1343.900 | |
= | 68.66 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Medtronic's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 94.17 | / | 68.655112174674 | |
= | 1.37 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Medtronic's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Fong Ivan K | officer: EVP GENERAL COUNSEL & SECR | 3M CENTER ST. PAUL MN 55144-1000 |
Kirk Jennifer M | officer: Chief Accounting Officer | 5 GREENWAY PLAZA SUITE 110 HOUSTON TX 77046 |
Lofton Kevin E | director | GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 |
Wall Brett A. | officer: EVP & Group Pres Restora Thera | 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Salmon Sean | officer: EVP & Group President Diabetes | MEDTRONIC PLC, 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432 |
Goldsmith Andrea Jo | director | 1220 AUGUSTA DRIVE SUITE 600 HOUSTON TX 77057 |
Liddicoat John R | officer: EVP & President of Americas | MEDTRONIC PLC 710 MEDTRONIC PKWY, MS LC300 MINNEAPOLIS MN 55432 |
White Robert John | officer: EVP & President MITG | MEDTRONIC PLC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Parkhill Karen L | officer: EVP & Chief Financial Officer | 1717 MAIN STREET, MC 6402 DALLAS TX 75201 |
Reddy Preetha | director | APOLLO HOSPITALS 21 GREAMS LN, OFF GREAMS RD CHENNAI K7 600006 |
Ellis Gary Lee | officer: EVP & Chief Financial Officer | THE TORO COMPANY 8111 LYNDALE AVENUE SOUTH BLOOMINGTON MN 55420 |
Hanson Bryan C | officer: EVP AND PRESIDENT, COVIDIEN | ZIMMER BIOMET HOLDINGS 345 E. MAIN STREET WARSAW IN 46580 |
Hakami Hooman | officer: EVP & Group President Diabetes | 710 MEDTRONIC PKWY MSLC300 MINNEAPOLIS MN 55432 |
Oconnell Christopher J | officer: See Remarks | MEDTRONIC, INC. 710 MEDTRONIC PKWY MINNEAPOLIS MN 55432 |
Lenehan James T | director | C/O MEDTRONIC INC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Other Sources
By tipranks.com 2022-03-06
By Zacks 2022-03-23
By Fool 2022-03-09
By tipranks.com 2022-03-21
By Zacks 2022-03-07
By tipranks.com 2022-03-10
By Zacks 2022-03-01
By Zacks 2022-03-28
By Zacks 2022-03-24
By Zacks 2022-02-22
By Zacks 2022-03-24
By Zacks 2022-04-01
By Zacks 2022-03-18
By Zacks 2022-03-21